Psoriasis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Psoriasis Market Outlook

Thelansis’s “Psoriasis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Psoriasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Psoriasis Overview

Psoriasis, affecting approximately 2-3% of the global population, is primarily an inflammatory skin condition characterized by abnormal epidermal differentiation and hyperproliferation. The disease's pathophysiology involves the activation and migration of T-cells to the dermis, leading to the release of cytokines, particularly tumor necrosis factor-alpha (TNF-alpha), which induces inflammation and accelerated skin cell production. This condition manifests with various symptoms, including dry, thick, raised patches on the skin covered by a silvery-white scale. These patches often provoke itching, especially in specific areas like the scalp, lower legs, and groin. In cases where psoriasis affects the hands and feet, painful fissures and cracks may develop, impairing manual tasks and walking. Severe psoriasis on the body can also lead to painful fissures and bleeding. Psoriasis is the most common autoimmune disease attributed to an inappropriate activation of the cellular immune system. The disease's development hinges on the activation and migration of T cells to the dermal layer, which triggers cytokine release, instigating inflammation and the rapid proliferation of skin cells. The precise trigger for T cell activation remains unknown, but it has long been recognized as a pivotal factor in the disease's pathogenesis. Numerous clinical studies involving a range of immune-modulating biological agents have been conducted to explore the role of T lymphocytes in psoriasis patients.

• The prevalence of Psoriasis varies from 2560 to 3250 cases per 100,000 populations in the USA, with a low diagnosis rate of ~49%.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: